US Pharma MarketingRather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.
Source: PharmaVoice